Talecris blood clot treatment gets orphan drug designation in Europe
Links shared publicly online about this topic.
- 465total visits
Talecris blood clot treatment gets orphan drug designation in Europe
North Carolina biotech company Talecris Biotherapeutics has received an orphan drug designation in Europe for a blood clot treatment under development. Talecris is developing Plasmin to treat acute peripheral arterial occlusion.
View full resource at medcitynews.com
Tags: Thrombotic Event, Blood Clot, Drug, Biotech
Most Recently Shared on March 12, 2011 at 7:05 pm By:
Talecris blood clot treatment gets orphan drug designation in Europe http://bit.ly/hTKXqJ
Advertisement
